Taro Pharmaceutical Industries (NYSE:TARO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a report published on Sunday morning. The firm issued a strong-buy rating on the stock.

Taro Pharmaceutical Industries Price Performance

TARO stock opened at $42.97 on Friday. Taro Pharmaceutical Industries has a 1-year low of $32.67 and a 1-year high of $45.76. The business has a fifty day moving average price of $42.64 and a 200-day moving average price of $42.29. The stock has a market capitalization of $1.62 billion, a P/E ratio of 29.84 and a beta of 0.56.

Taro Pharmaceutical Industries (NYSE:TARO) last posted its quarterly earnings results on Monday, May 20th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.12. Taro Pharmaceutical Industries had a return on equity of 3.75% and a net margin of 8.56%. The firm had revenue of $164.94 million during the quarter, compared to analysts’ expectations of $156.10 million.

Institutional Trading of Taro Pharmaceutical Industries

Several large investors have recently modified their holdings of the company. California State Teachers Retirement System grew its holdings in Taro Pharmaceutical Industries by 2.3% during the first quarter. California State Teachers Retirement System now owns 11,323 shares of the company’s stock valued at $479,000 after purchasing an additional 252 shares during the period. Harvest Management LLC grew its holdings in Taro Pharmaceutical Industries by 3.9% during the fourth quarter. Harvest Management LLC now owns 7,380 shares of the company’s stock valued at $308,000 after purchasing an additional 274 shares during the period. Inspire Advisors LLC grew its holdings in Taro Pharmaceutical Industries by 5.9% during the first quarter. Inspire Advisors LLC now owns 14,495 shares of the company’s stock valued at $614,000 after purchasing an additional 813 shares during the period. SG Americas Securities LLC grew its holdings in Taro Pharmaceutical Industries by 24.5% during the fourth quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock valued at $195,000 after purchasing an additional 921 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in Taro Pharmaceutical Industries by 77.9% during the first quarter. BNP Paribas Financial Markets now owns 4,107 shares of the company’s stock valued at $174,000 after purchasing an additional 1,799 shares during the period. Institutional investors own 91.40% of the company’s stock.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.